Lyell Total Revenue from 2010 to 2024
| LYEL Stock | USD 1.51 0.05 3.21% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 130 K | Current Value 123.5 K | Quarterly Volatility 21.6 M |
Check Lyell Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lyell Immunopharma's main balance sheet or income statement drivers, such as Net Interest Income of 24.6 M, Interest Income of 24.6 M or Depreciation And Amortization of 13.9 M, as well as many indicators such as Price To Sales Ratio of 2.4 K, Dividend Yield of 0.0 or PTB Ratio of 0.71. Lyell financial statements analysis is a perfect complement when working with Lyell Immunopharma Valuation or Volatility modules.
Lyell | Total Revenue |
Latest Lyell Immunopharma's Total Revenue Growth Pattern
Below is the plot of the Total Revenue of Lyell Immunopharma over the last few years. Total revenue comprises all receipts Lyell Immunopharma generated from the sale of its products or services. It is the total amount of income generated by the sale of goods or services related to the company's primary operations. Lyell Immunopharma's Total Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lyell Immunopharma's overall financial position and show how it may be relating to other accounts over time.
| Total Revenue | 10 Years Trend |
|
Total Revenue |
| Timeline |
Lyell Total Revenue Regression Statistics
| Arithmetic Mean | 7,327,500 | |
| Geometric Mean | 1,035,309 | |
| Coefficient Of Variation | 295.05 | |
| Mean Deviation | 10,814,200 | |
| Median | 657,000 | |
| Standard Deviation | 21,619,689 | |
| Sample Variance | 467.4T | |
| Range | 84.6M | |
| R-Value | 0.35 | |
| Mean Square Error | 441.5T | |
| R-Squared | 0.12 | |
| Significance | 0.20 | |
| Slope | 1,694,652 | |
| Total Sum of Squares | 6543.8T |
Lyell Total Revenue History
About Lyell Immunopharma Financial Statements
Lyell Immunopharma investors utilize fundamental indicators, such as Total Revenue, to predict how Lyell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 130 K | 123.5 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Lyell Stock
When determining whether Lyell Immunopharma is a strong investment it is important to analyze Lyell Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lyell Immunopharma's future performance. For an informed investment choice regarding Lyell Stock, refer to the following important reports:Check out the analysis of Lyell Immunopharma Correlation against competitors. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Quarterly Revenue Growth (0.52) | Return On Assets (0.19) | Return On Equity (0.32) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.